SkBQ - prooxidant addressed to mitochondria

Area of Science:

• Mitochondrial biochemistry
• Cellular metabolism
• Drug discovery

Background:

• Oxidative stress and mitochondrial dysfunction are central to various pathologies.
• Targeting mitochondria with specific compounds offers therapeutic potential for inherited and age-related diseases.
• Lipophilic cations, particularly benzoquinone derivatives, are explored for their antioxidant properties.

Purpose of the Study:

• To synthesize and evaluate a novel benzoquinone derivative (SkBQ) for its biological activity.
• To compare the antioxidant and prooxidant effects of SkBQ with related compounds (SkQ1, SkQT1).
• To investigate the potential of SkBQ as a mitochondria-targeted therapeutic agent, possibly for cancer treatment.

Main Methods:

• Synthesis of a novel benzoquinone derivative (SkBQ) conjugated with decyltriphenylphosphonium.
• Experiments on isolated mitochondria to assess antioxidant/prooxidant activity and effects on membrane potential.
• Cell culture studies using human fibroblasts to evaluate protection against hydrogen peroxide-induced apoptosis.

Main Results:

• SkBQ demonstrated significantly lower antioxidant and higher prooxidant activity compared to SkQ1 and SkQT1.
• SkBQ, similar to SkQ1 and SkQT1, interacts with Complex III of the respiratory chain and reduces mitochondrial membrane potential.
• SkBQ failed to protect human fibroblasts from oxidative stress, whereas SkQ1 and SkQT1 showed a protective effect.

Conclusions:

• SkBQ functions as a mitochondria-targeted prooxidant, contrasting with the antioxidant properties of SkQ1 and SkQT1.
• The structural modifications in SkBQ alter its biological activity, highlighting the importance of substituent positioning.
• SkBQ's prooxidant nature suggests potential applications in treating cancers sensitive to mitochondrial reactive oxygen species, such as prostate cancer.